Seeking Alpha
 

Alere Inc. (ALR)

- NYSE
  • Sep. 15, 2014, 12:48 PM
    • Diagnostics maker Alere (ALR +12.9%) bucks biotech's down day by jumping on a 6x surge in volume on reports that former CEO Ron Zwanziger intends to bid $46 per share for the company. His potential offer would value Alere at almost $4B.
    • Mr. Zwanziger believes the firm is undervalued. He has a point. Alere's sales and earnings are decelerating and its P/S, P/B and P/CF ratios all lag the industry according to msn money.
    | Comment!
  • Jun. 10, 2013, 7:54 AM
    More on Coppersmith-Alere (ALR) letter: Coppersmith wants Alere to use the proceeds from any sales to slash its debt, which is almost $3.8B vs a market cap of $2.15B. The ops that Coppersmith wants Alere to sell are its health care management unit, its consumer products joint venture with P&G (PG), and possibly its toxicology unit. Coppersmith has been agitating for change since last month and has nominated three directors to Alere's board.
    | Comment!
Visit Seeking Alpha's
ALR vs. ETF Alternatives
Company Description
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.